Blog Archives

Ulcerative Colitis Study: New Faecal Calprotectin Cut-offs

BÜHLMANN IBDoc®: Walsh, A, Kormilitzin, A. et al. New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC).  13th Congress of ECCO 2018, Feb 14 – 17, 2018. Vienna, Austria. Highlights from this Poster “Conclusions. An FCal <180 g/g is indicative of endoscopic and histological remission. FCal
Continue Reading →

The Advantages of an Immunoturbidimetric Assay for Measuring Calprotectin in Fecal Samples

An immunoturbidimetric assay (or particle-enhanced turbidimetric immunoassay (PETIA)) for measuring Calprotectin is the fastest solution in the market with the shortest time to first result regardless of using sample batches or random access.

Continue Reading →

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Continue Reading →

Point of Care Testing of Fecal Calprotectin as a Substitute for Routine Laboratory Analysis

BÜHLMANN fCAL® turbo and IBDoc®: Hejla, J, Theedeb, K, et al.  Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis.  Practical Laboratory Medicine; 10 (2018) 10-14. PMID: 29234707 DOI: 10.1016/j.plabm.2017.11.002 Highlights from this Publication “This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients. Point of care
Continue Reading →